Research

Mixed

Combining GLP-1 pharmacotherapy with promyogenic agents (e.g., bimagrumab, enobosarm), structured resistance exercise, and targeted nutrition (protein/HMB) mitigates lean mass loss and improves functional outcomes compared to GLP-1 monotherapy.

Do not rely on GLP-1 medication alone. To protect your muscles and strength, you must combine your medication with resistance exercise, ensure you are eating enough protein, and ask your doctor about emerging combination therapies like promyogenic agents that specifically target muscle preservation.

ModerateSupportsMEDIUM confidence
combining enobosarm with semaglutide reduced lean mass loss by 71% and yielded a 27% greater reduction in fat mass compared to semaglutide alone. Notably, this combination also led to superior preservation of stair-climbing power and lower-extremity strength
Kieran F. Reid et al. · Frontiers in Aging · 2025

Why this rating

Cites specific trials (QUALITY, bimagrumab RCT) but notes these are emerging strategies requiring further investigation.

Source

Moving beyond the scale: musculoskeletal risks, evidence gaps and emerging combination strategies to optimize the quality of weight loss pharmacotherapy in older adults

Kieran F. Reid et al. · Frontiers in Aging · 2025

DOI 10.3389/fragi.2025.1640030

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →